Ingmar Bruns
Known title: Chief Medical OfficerCIK: 0001838041
Ingmar Bruns's purchase track record
Ingmar Bruns has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/6/2025 | ZNTL | $46K | -41.7% | -32.9% | +4.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZNTL | ▲ Buy | Grant | 9,727 | $21K | 9/30/2026 | View on chart |
| ZNTL | ▼ Sell | Open Market | 335 | $802 | 2/9/2026 | View on chart |
| ZNTL | ▼ Sell | Open Market | 2,962 | $7K | 2/6/2026 | View on chart |
| ZNTL | ▲ Buy | Open Market | 20,000 | $46K | 2/6/2025 | View on chart |
| ZNTL | ▲ Buy | Grant | 16,629 | $0 | 2/3/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.